GC Cell

GC Cell Liabilities

The The Liabilities of GC Cell (144510.KQ) as of Oct 27, 2026 is 113.31 B KRW. In the previous year, The Liabilities was 120.56 B KRW — a change of -6.01% (lower).

Liabilities

113.31 BKRW

YoY

-6.01%

Last updated:

In 2025, GC Cell's total liabilities amounted to 113.31 B KRW, a -6.01% difference from the 120.56 B KRW total liabilities in the previous year.

The GC Cell Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
9.55 B KRW
Jan 1, 2019
24.02 B KRW
Jan 1, 2020
29.19 B KRW
Jan 1, 2021
134.57 B KRW
Jan 1, 2022
138.07 B KRW
Jan 1, 2023
123.69 B KRW
Jan 1, 2024
120.56 B KRW
Jan 1, 2025
113.31 B KRW
The GC Cell Liabilities history
YEARLiabilitiesYoY
113.31 BKRW-6.01%
120.56 BKRW-2.53%
123.69 BKRW-10.42%
138.07 BKRW+2.60%
134.57 BKRW+360.97%
29.19 BKRW+21.56%
24.02 BKRW+151.56%
9.55 BKRW+35.76%
7.03 BKRW+9.59%
6.42 BKRW-18.81%
7.90 BKRW+1.13%
7.82 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GC Cell Stock analysis

What does GC Cell do? GC Cell Corp generates revenue through four business segments. The Specimen Testing Service segment offers sample testing, clinical trial support, and veterinary testing services to clients in healthcare and research sectors. The Cell Therapy segment provides cell culture solutions and technology transfer services to biotechnology firms. The Cord Blood Storage segment delivers cord blood storage services primarily to expectant parents and medical institutions. The Other Business segment handles bio-logistics services and related operations for healthcare providers. The company's revenue streams are derived from direct contracts with healthcare organizations, biotech companies, and individual clients seeking specialized testing and storage solutions. Clients include hospitals, research institutions, and private individuals requiring cord blood preservation. The firm's business model focuses on providing specialized services within the life sciences sector without relying on external partnerships or third-party platforms. GC Cell Corp's product offerings are tailored to specific industry needs, with each segment targeting distinct client groups. The Specimen Testing Service segment serves clients needing laboratory analysis, while the Cell Therapy segment supports biotech innovation through technology transfer. The Cord Blood Storage segment caters to consumer demand for personal health preservation, and the Other Business segment facilitates logistics for medical supply chains. GC Cell is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing GC Cell's Liabilities

GC Cell's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating GC Cell's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing GC Cell's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

GC Cell's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in GC Cell’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about GC Cell stock

The Liabilities of GC Cell is 113.31 B KRW in 2025.

The Liabilities of GC Cell changed from 120.56 B KRW to 113.31 B KRW, representing a -6.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities GC Cell since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's GC Cell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — GC Cell

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — GC Cell